Long-term clinical and biological outcomes in children vertically infected with HIV

HIV Treat Bull - Vol. 7, No. 5, May 2006

Few clinical and biological data are available for adolescents living with HIV since birth.

Since 1986, the French Paediatric Cohort (EPF) prospectively enrolled HIV positive women who delivered at 90 centres across France, and followed all vertically infected children on a long-term basis.

Catherine Dollfus and coworkers from EPF authored a poster presenting an analysis of the subgroup of older children and adolescents still alive in this cohort, born before 1993, with last data collected after January 2003. The authors reported, that of the 293 children born before 1993, 171 children were still alive with a median age of 14.5 years (IQR: 13.0-16.5 years)

About a quarter of children were born to mothers originating from sub-Saharan Africa and 11% from the Caribbean, with the remaining 63% born to Caucasian mothers.

A history of CDC category C diagnosis was reported for 18% of the children, with no difference between genders or ethnicities. The majority of the children (92%) initially received AZT mono-therapy, 56% of children were treated from birth and subsequently 87% children received HAART (36% between the ages of 3 and 7 years).

At last visit, 77% were receiving HAART and 19% dual therapy. Only 3.5% had never received antiretroviral therapy. Of those receiving HAART (n=131), 80 (61%) received 2 NRTI + 1 PI; 26 (20%) received 2 NRTI +1 NNRTI; 5 (4%) received 3 NRTIs and 20 (15%) other combinations.

Overall 60.6% of the children had CD4 count >/= 500 cells/mm³; 31.5% had CD4 count 200-300 cells/mm³ in and 7.9% [95%CI: 3.8-12.0] of children had a CD4 count of <200 cells/mm³.

Viral load was <50 copies/mL in 40.4% [95% CI: 32.9-47.8%] of the children; 50-1000 copies/mL in 16.9% of children; 1000-30,000 in 27.7%, and 15% of children had viral load >30,000 [95% CI: 9.6-20.5] copies/mL

EPF is one of the largest cohorts of children followed in the long term since birth. The authors wrote: “Despite a long period of suboptimal antiretroviral treatment, immunological and virological status of most adolescents still alive is rather satisfactory.”

COMMENT

It would be interesting to see an analysis of the 20 children receiving “other combinations” in this subgroup, which would be expected to be more complex and salvage therapy.

Ref: Dollfus C, Le Chenadec J, Faye A et al. Long-term clinical and biological outcomes in children vertically infected with HIV. 13th CROI, Denver, 2006. Abstract 683.

2008-03-10
IB060705-21

©2008. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.